UNSPSC 51282917: Fandofloxacin

This classification denotes a quinolone antibiotic with the molecular formula C20H18F2N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, I6406OC637 chemically known as 6-fluoro-1-(5-fluoro-2-pyridyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid but generally known as fandofloxacin, which bears US NIH Compound Identifier 178087. European Medicines Agency schedules Fandofloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07508MIG.

UNSPSC 51282917 Fandofloxacin, a Commodity code, shows minimal relevant recent activity in state and local procurement. The recent opportunities tagged to this code do not align with procurement of fandofloxacin — an antibiotic used in veterinary and human medicine — but instead reflect broader pharmaceutical, medical supply, and healthcare program solicitations. Seminole County, Florida's IFB for naloxone and drug deactivation systems, the City of Tampa's ITB for medical and first aid supplies serving the Fire Department Rescue Division, the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products all involve pharmaceutical procurement but do not specifically target fandofloxacin or related fluoroquinolone products. State and local purchasing under this code does not currently reflect documented demand for this commodity.

The mismatch between the code's nominal scope and the recent opportunities tagged to it suggests either category-assignment inconsistency in source systems or absence of active procurement specifically for fandofloxacin at the state and local level. Business development professionals evaluating this code should rely on direct market research into state health department formularies, institutional pharmacy purchasing agreements, and veterinary licensing boards rather than on recent competitive solicitations. No representative fandofloxacin-specific RFP, RFQ, IFB, or ITB emerges from the recent-opportunities record.